1. Treatment of chronic hepatitis B: recommendations from an Italian workshop
- Author
-
Carosi, G., Rizzetto, M., Andreone, P., Angelico, M., Ascione, A., Caporaso, N., Fagiuolim, S., Fattovich, G., Mondelli, M., Niro, G. A., Pontisso, P., Bonino, F., Perno, C. F., Prati, D., Andreoni, M., Angarano, G., Annicchiarico, E., Boncoraglio, R., Brustia, D., Calabrese, N., Carlotto, A., Cavalletto, L., Cavina, M., Chessa, L., Croce, G., De Sanctis, G., Di Candilo, F., Fabris, P., Fracassetti, O., Lanza, A. G., Giuberti, T., Guazzotti, G., Iacovazzi, T., Iovinella, V., Izzi, A., Loperfido, P., Magni, C. F., Marino, N., Messina, V., Michelone, G., Morante, R., Moretti, A., Nasta, P., Nauri, L., Paffetti, A., Pasino, M., Perboni, G., Petrelli, E., Picciotto, A., Pozzi, M., Purificato, F., Re, T., Rinaldi, R., Sani, S., Santoro, R., Schioppa, O., Scotto, G., Siciliano, M., Sorbello, O., Squadrito, G., Taddei, M. T., Traversa, A., Tundo, P., Venezia, G., Vilardo, L., Zignego, A. L., Zoncada, A., and Zuin, M.
- Subjects
Liver Cirrhosis ,medicine.medical_specialty ,Cirrhosis ,Immune suppressed ,Human immunodeficiency virus (HIV) ,HIV Infections ,Disease ,Antiviral therapy ,medicine.disease_cause ,Antiviral Agents ,Immunocompromised Host ,Hepatitis B, Chronic ,Chronic hepatitis ,Interferon ,HDV ,Internal medicine ,Drug Resistance, Viral ,HBV ,medicine ,Humans ,Hepatitis B Antibodies ,Liver histology ,Hepatitis B virus ,HCV ,HIV ,Hepatology ,business.industry ,Gastroenterology ,Hepatitis B ,medicine.disease ,Hepatitis C ,Hepatitis D ,Italy ,Immunology ,business ,medicine.drug - Abstract
The changing scenario of hepatitis B virus therapy has encouraged the organisation of a workshop, endorsed by three Italian scientific societies, aimed at defining the current recommendations for hepatitis B virus treatment. Liver histology and stage of disease remain fundamental for treatment decisions; interferon and nucleoside/nucleotide analogues-based therapy represent different strategies for different phases of the hepatitis B virus disease. The recommendations defined: new and lower cut-off of hepatitis B virus–DNA for eligibility to therapy according to disease stage, how to optimise the use of nucleoside/nucleotide analogues and to individualise the monitoring of response and what to do with treatment failures. Specific recommendations have also been given for cirrhosis patients, those immune suppressed and co-infected with HIV and other hepatitis viruses. © 2008 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
- Published
- 2008